Clinical Trials Logo

Bacterial Infections clinical trials

View clinical trials related to Bacterial Infections.

Filter by:

NCT ID: NCT00081744 Completed - Clinical trials for Gram-Positive Bacterial Infections

Study Comparing Tigecycline to Imipenem/Cilastatin in Complicated Intra-Abdominal Infections in Hospitalized Subjects

Start date: November 2002
Phase: Phase 3
Study type: Interventional

Purpose: To provide a mechanism for the emergency use of tigecycline in the appropriate clinical situations.

NCT ID: NCT00079989 Completed - Clinical trials for Gram-Negative Bacterial Infections

Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms

Start date: December 2003
Phase: Phase 3
Study type: Interventional

To evaluate the safety and efficacy of tigecycline in the treatment of subjects with selected serious infections caused by resistant gram-negative bacteria, eg, Acinetobacter baumannii, Enterobacter species, Klebsiella pneumoniae or other resistant gram-negative pathogens, for whom antibiotics have failed or who cannot tolerate other appropriate antimicrobial therapies. The primary efficacy endpoint will be the clinical response.

NCT ID: NCT00079976 Completed - Clinical trials for Gram-Positive Bacterial Infections

Study Evaluating Tigecycline in Selected Serious Infections Caused by Vancomycin-Resistant Enterococcus (VRE) or Methicillin-Resistant Staphylococcus Aureus (MRSA)

Start date: October 2003
Phase: Phase 3
Study type: Interventional

To evaluate the safety and efficacy of tigecycline in the treatment of selected serious infections caused by VRE. The primary efficacy endpoint will be the clinical response for all subjects.

NCT ID: NCT00062647 Completed - Clinical trials for Gram-Positive Bacterial Infections

Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia

ASSURE
Start date: August 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.

NCT ID: NCT00055198 Terminated - Clinical trials for Gram-Positive Bacterial Infections

Daptomycin for the Treatment of Infections Due to Gram-Positive Bacteria

Start date: December 19, 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to provide daptomycin, an antibiotic, to patients who are failing conventional therapy, or who cannot take approved antibiotics for one reason or another.

NCT ID: NCT00044928 Completed - Clinical trials for Bacterial Infections

Study Evaluating Zosyn in Hospitalized Patients With Intra-abdominal Infection

Start date: July 2002
Phase: Phase 4
Study type: Interventional

A Phase IV, multicenter study of hospitalized patients with complicated intra-abdominal infection.

NCT ID: NCT00037050 Completed - Clinical trials for Bacterial Infections

Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria

Start date: April 2002
Phase: Phase 3
Study type: Interventional

This study will treat patients who have a short term central catheter that is thought to be infected with a specific bacteria (gram positive bacteria)

NCT ID: NCT00035854 Completed - Clinical trials for Bacterial Infections

New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)

Start date: February 2002
Phase: Phase 3
Study type: Interventional

This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)

NCT ID: NCT00035269 Completed - Clinical trials for Gram-positive Bacterial Infections

New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)

Start date: December 2001
Phase: Phase 3
Study type: Interventional

This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)

NCT ID: NCT00008853 Completed - Clinical trials for Bacterial Infections

Evaluation of Two Type III GBS Polysaccharide-Tetanus Toxoid Conjugate Vaccines

Start date: n/a
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and favorable immune response to an anti-streptococcal vaccine (a vaccine that treats a common bacterial infection) in healthy non-pregnant women. Group B Streptococcus (GBS) continues to be the single most frequent cause of life-threatening bacterial infection during the first 2 months of life. Further, GBS pregnancy-related morbidity afflicts more than 50,000 women annually in the US. Therefore, active immunization of women is an appealing strategy for the prevention of GBS disease in pregnant women and their infants during the first 3 months of infant life.